Context Therapeutics
Context is dedicated to developing the next generation of T cell engaging (TCE) bispecific antibody therapies to treat solid tumors.
News & Media — Context Therapeutics
Summary collection of all news articles about Context Therapeutics.
CTIM-76 Program - Context Therapeutics
Nov 3, 2023 · Context’s lead candidate, CTIM-76, is a CLDN6 x CD3 bispecific antibody that incorporates a highly selective CLDN6 binding arm and a CD3 binding single-chain Fv domain in an IgG format with a silenced Fc that is designed to be functionally monovalent to avoid aberrant T-cell activation and to enhance the safety profile.
Clinical Trial Manager, Clinical Operations - Context Therapeutics
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a ...
Partnering - Context Therapeutics
Selective product in-licensing or acquisition will enable Context Therapeutics to rapidly build a diversified pipeline of T cell engaging bispecific antibodies to treat solid tumors.
SVP, Development — Context Therapeutics
Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody.
CT-202 — Context Therapeutics
Many therapies targeting Nectin-4 are being developed due to its ubiquitous expression in several types of cancers. These therapies, however, display a high rate of drug related toxicities due to binding in healthy skin tissue, accentuating the need for alternative approaches of anti-cancer therapeutics targeting Nectin-4.
Director, Program Management — Context Therapeutics
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a ...
About — Context Therapeutics
Our Purpose Our purpose is what weaves us together. It is the single most important reason we come to work each day. We are united by our passion for helping patients with cancer. They deserve better. Their families deserve better. It is our job to help them. We believe it is possible. We will find a way.
Contact — Context Therapeutics
Context Therapeutics is based in Philadelphia, PA. You can reach us by email at [email protected].